KR20200102982A - 보존된 박출률을 갖는 심부전의 치료 방법 - Google Patents

보존된 박출률을 갖는 심부전의 치료 방법 Download PDF

Info

Publication number
KR20200102982A
KR20200102982A KR1020207011597A KR20207011597A KR20200102982A KR 20200102982 A KR20200102982 A KR 20200102982A KR 1020207011597 A KR1020207011597 A KR 1020207011597A KR 20207011597 A KR20207011597 A KR 20207011597A KR 20200102982 A KR20200102982 A KR 20200102982A
Authority
KR
South Korea
Prior art keywords
patient
day
hfpef
imeglimine
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207011597A
Other languages
English (en)
Korean (ko)
Inventor
소피 할라코우-보제크
Original Assignee
폭셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 폭셀 filed Critical 폭셀
Publication of KR20200102982A publication Critical patent/KR20200102982A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207011597A 2017-10-02 2018-10-02 보존된 박출률을 갖는 심부전의 치료 방법 Ceased KR20200102982A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762566668P 2017-10-02 2017-10-02
US62/566,668 2017-10-02
PCT/IB2018/057648 WO2019069230A1 (en) 2017-10-02 2018-10-02 METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION

Publications (1)

Publication Number Publication Date
KR20200102982A true KR20200102982A (ko) 2020-09-01

Family

ID=63963334

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011597A Ceased KR20200102982A (ko) 2017-10-02 2018-10-02 보존된 박출률을 갖는 심부전의 치료 방법

Country Status (12)

Country Link
US (1) US11617754B2 (https=)
EP (1) EP3691650A1 (https=)
JP (1) JP2020536121A (https=)
KR (1) KR20200102982A (https=)
CN (1) CN111163782A (https=)
BR (1) BR112020006472A2 (https=)
CA (1) CA3078163A1 (https=)
IL (1) IL273723A (https=)
MX (1) MX2020003243A (https=)
TW (1) TW201924689A (https=)
WO (1) WO2019069230A1 (https=)
ZA (1) ZA202002292B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
CA3103324A1 (en) 2018-06-14 2019-12-19 Poxel Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
CN115770062B (zh) * 2021-09-07 2025-10-10 深圳迈瑞生物医疗电子股份有限公司 一种超声波数据的处理方法、成像装置
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804113B1 (fr) 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
FR2896157B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
KR101618198B1 (ko) 2008-05-23 2016-05-04 뽁셀 에스아에스 3,6-디히드로-1,3,5-트리아진 유도체의 제조방법
BRPI0916197B1 (pt) 2008-07-29 2018-01-23 Poxel Processo para isolar componentes enantioméricos de uma mistura de enantiômeros
TW201033182A (en) 2008-12-12 2010-09-16 Poxel Tetrahydrotriazine compounds for treating diseases associated with AMPK activity
US8592370B2 (en) 2008-12-12 2013-11-26 Poxel S.A.S. Combination of insulin with triazine derivatives
JP5536869B2 (ja) 2009-03-26 2014-07-02 ポクセル・エスアーエス 優先晶出法を利用したジヒドロ−１，３，５トリアジンラセミ体のエナンチオマー分離のための方法
FR2948027A1 (fr) * 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
WO2011154496A1 (en) * 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
US8742103B2 (en) 2010-12-01 2014-06-03 Poxel Separation of triazine derivatives enantiomers using tartaric acid
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US20160151461A1 (en) * 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP3110449B1 (en) * 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
US10285973B2 (en) 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
BR112018016001A2 (en) * 2016-03-16 2018-12-18 Boehringer Ingelheim International Gmbh pharmaceutical composition, treatment methods and uses thereof
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
MY203360A (en) 2018-06-06 2024-06-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease

Also Published As

Publication number Publication date
WO2019069230A1 (en) 2019-04-11
CA3078163A1 (en) 2019-04-11
IL273723A (en) 2020-05-31
CN111163782A (zh) 2020-05-15
TW201924689A (zh) 2019-07-01
US11617754B2 (en) 2023-04-04
US20200316078A1 (en) 2020-10-08
MX2020003243A (es) 2020-09-18
JP2020536121A (ja) 2020-12-10
EP3691650A1 (en) 2020-08-12
BR112020006472A2 (pt) 2020-10-06
ZA202002292B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
Hammoudi et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes
KR20200102982A (ko) 보존된 박출률을 갖는 심부전의 치료 방법
Bracey et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin‐1β
Wu et al. Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats
Jadhav et al. The heme oxygenase system selectively enhances the anti-inflammatory macrophage-M2 phenotype, reduces pericardial adiposity, and ameliorated cardiac injury in diabetic cardiomyopathy in Zucker diabetic fatty rats
AU2014244053B2 (en) Treatment of a diastolic cardiac dysfunction with a TRPV2 receptor agonist
Lin et al. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia
JP7508496B2 (ja) 心筋症、収縮期心機能不全及びうっ血性心不全症状の治療のためのプロベネシド
CN110167538B (zh) 用于治疗心血管疾病的方法
Caldwell et al. Aerobic exercise training reduces cardiac function and coronary flow-induced vasodilation in mice lacking adiponectin
Carrick-Ranson et al. Effects of aging and endurance exercise training on cardiorespiratory fitness and cardiac structure and function in healthy midlife and older women
JP6441818B2 (ja) 心不全の治療法
Thackeray et al. Insulin restores myocardial presynaptic sympathetic neuronal integrity in insulin-resistant diabetic rats
Stevens et al. Exercise improves cardiac function and attenuates insulin resistance in Dahl salt-sensitive rats
He et al. Susceptibility to intracerebral hemorrhage-induced brain injury segregates with low aerobic capacity in rats
Levijoki et al. Levosimendan alone and in combination with valsartan prevents stroke in Dahl salt-sensitive rats
HK40022791A (en) Methods of treating heart failure with preserved ejection fraction
US12564615B2 (en) Treatment method for cardiac hypertrophy
US20160067246A1 (en) Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
Limón-Bernal et al. Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat
Azza et al. Echocardiographic assessment of epicardial adipose tissue in obese children and its relation to clinical parameters of the metabolic syndrome
Dauz The Role of Transforming-growth Factor Beta 1 and Platelet-derived Growth Factor in Right Ventricular Remodeling in Response to Right Ventricular Pressure and Volume-loading
US20220193065A1 (en) Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
Cops Development and characterization of a clinically relevant rat model of diabetic cardiomyopathy
JP2020158405A (ja) 糖尿病性腎症の治療薬

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200422

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210910

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231004

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240501

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20231004

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I